Phase 2TerminatedINTERVENTIONAL
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
ClinicalTrials.gov · NCT06865677 · Registry updated: 2026-01-21
- Condition / research focus
- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma; Recurrent Epithelial Endometrial Carcinoma; Recurrent Epithelial Cervical Carcinoma
- Sponsor
- National Cancer Institute (NCI)
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2025-06-09. Completion: 2025-07-01 (may be estimated). Results are posted in this registry.
Products and interventions (9)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Sacituzumab Govitecan (drug) — also listed as: Trodelvy
- EKG (diagnostic_test) — also listed as: Electrocardiogram
- Brain MRI (diagnostic_test) — also listed as: Brain magnetic resonance imaging
- CT scans (diagnostic_test) — also listed as: Computed tomography scans
- Tumor biopsy (procedure) — also listed as: Tumor bx
- Loperamide (drug) — also listed as: Immodium
- Octreotide (drug) — also listed as: Sandostatin, Bynfezia, Mycapssa
- Diphenoxylate/Atropine (drug) — also listed as: Lomotil